口服抗凝药阿哌沙班片获批上市

In 2021, the State Food and Drug Administration approved the issuance of the "Drug Registration Certificate" for apixaban tablets (Eliquis). It is mainly used for the prevention of venous thromboembolic events (VTE) in adult patients undergoing elective hip or knee replacement surgery.

Apixaban tablets (Eliquis), jointly developed by Bristol-Myers Squibb and Pfizer, are a new type of oral factor Xa inhibitor with good efficacy, high selectivity and low risk of bleeding. Apixaban has a strong inhibitory effect on factor Xa. Even factor Xa bound to thrombus can be inhibited by apixaban, thereby preventing prothrombin from being activated into thrombin.

Apixaban (Eliquis) does not directly inhibit platelet aggregation and adhesion, but it can inhibit platelet aggregation indirectly by inhibiting the activation of thrombin. The mechanism of action of apixaban is mainly by occupying the active site of factor Xa, inhibiting the activation of factor Xa, and producing an anticoagulant effect.

96 patients with pulmonary embolism were selected. The patients were divided into the control group using a random number table, which was treated with reteplase combined with warfarin, and the observation group, which was treated with apixaban combined with reteplase. Results: The effective rate of the observation group was 89.58%, which was higher than 70.83% of the control group (P<0.05); the incidence of adverse reactions in the observation group was 22.925%, which was lower than 41.67% of the control group, and the differences were statistically significant (all P<0.05).

It is concluded that apixaban tablets combined with reteplase has ideal efficacy and improvement of coagulation function in patients with acute pulmonary embolism, and the bleeding rate of patients is lower than that of warfarin.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.